Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EBT Margin for 10 consecutive years, with 58.71% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 31998.0% to 58.71% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 83.95% through Dec 2025, down 8324.0% year-over-year, with the annual reading at 83.95% for FY2025, 8324.0% down from the prior year.
  • EBT Margin for Q4 2025 was 58.71% at Ultragenyx Pharmaceutical, up from 112.26% in the prior quarter.
  • The five-year high for EBT Margin was 378.76% in Q4 2023, with the low at 263.3% in Q3 2022.
  • Average EBT Margin over 5 years is 90.74%, with a median of 138.41% recorded in 2021.
  • The sharpest move saw EBT Margin soared 52871bps in 2023, then crashed -31998bps in 2025.
  • Over 5 years, EBT Margin stood at 149.63% in 2021, then fell by 0bps to 149.95% in 2022, then surged by 353bps to 378.76% in 2023, then crashed by -31bps to 261.28% in 2024, then tumbled by -122bps to 58.71% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 58.71%, 112.26%, and 68.47% for Q4 2025, Q3 2025, and Q2 2025 respectively.